FDA Approves Eflapegrastim-xnst Injection for Chemotherapy-Induced Neutropenia

FDA Approves Eflapegrastim-xnst Injection for Chemotherapy-Induced Neutropenia

header-info

The FDA approved eflapegrastim-xnst injection—a long-acting granulocyte colony-stimulating factor (G-CSF) with a novel formulation—to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia.